The Max Foundation is excited to include Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD as the newest Strategic Innovation Advisory Board member.
Graciela Mabel Woloj Rothstein is an experienced leader with a demonstrated history of working within the pharmaceuticals industry. Rothstein brings her expertise in the fields of Oncology, Good Clinical Practice (GCP), Pharmacovigilance, Clinical Trial Management System (CTMS), and Biotechnology.
Dr. Mikkel Z Oestergaard is Director of Health Technology Assessment (HTA) Statistics within the Department of Biostatistics and Research Decision Sciences at Merck/MSD and is based in Zurich, Switzerland. He has 16 years of professional experience and more than 40 peer-reviewed scientific publications in the areas of clinical drug development, health statistics and evidence-generation for public health impact. Dr. Oestergaard previously worked at the World Health Organization (WHO) headquarter before subsequently moving to the pharmaceutical industry. At the WHO he focused on evaluation of the global burden of disease, and co-founded WHO’s Global Initiative on Genomics for Public Health.
We are eager to learn from Rothstein and Oestergaard’s knowledge and experience in the pharmaceutical industry, in order to bring more access to treatment for patients worldwide. Join us in welcoming Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD to our advisory board!
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Andrielle Yost, Associate Director of Public Sector Engagement at The Max Foundation, discusses the work the organization is doing to improve access to chronic lymphocytic leukemia (CLL) treatment for patients in low- and middle-income countries (LMICs). Watch the interview here. You can also watch….
Tanner Pharma Group will serve as the title sponsor for The Max Foundation’s 2018 campaign “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.
“Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.
